Literature DB >> 12855649

Immune-mediated tumor regression induced by CpG-containing oligodeoxynucleotides.

Jonathan Baines1, Esteban Celis.   

Abstract

T-cell based immunotherapy is an attractive approach for the treatment of multiple tumor types including cervical carcinoma. Immunostimulating DNA containing unmethylated cytosine-guanine (CpG) motifs have been successfully used as adjuvants to enhance immune responses to vaccines designed to trigger antitumor T-cell responses. Using a murine model of cervical carcinoma, we report here that repeated administration of synthetic oligodeoxynucleotides bearing CpG motifs (CpG-ODNs) without the need of vaccination into animals bearing large, established tumors resulted in significant antitumor effects. Both tumor regressions and extended survival resulting from CpG-ODN therapy required the participation of CD8+ T cells. On the other hand, CD4+ T cells were not only not required, but also appeared to inhibit the therapeutic effect of CpG-ODN. Tumor regression correlated with increased infiltration of CD8+ T cells into the tumors and with enhanced expression of MHC class I and II antigens by the tumor cells. Together, these results indicate that CpG therapy could be promising as a single agent for the treatment of some tumors such as cervical carcinoma.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12855649

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  40 in total

1.  Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides.

Authors:  Arthur M Krieg
Journal:  Curr Oncol Rep       Date:  2004-03       Impact factor: 5.075

2.  Immunostimulatory and anti-neoplasm effects of a novel palindrome CpG oligodeoxynucleotide in mice.

Authors:  Hai-yan Du; Li-hou Dong; Bi-jun Zhao; Jie Fu; Qing-qing Wang; Fang Chen; Lun Ou; Na Li; Xiao Sun; Zhong-ming Tang; Hai-feng Song
Journal:  Acta Pharmacol Sin       Date:  2012-06-25       Impact factor: 6.150

Review 3.  Development of TLR9 agonists for cancer therapy.

Authors:  Arthur M Krieg
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

Review 4.  Synthetic oligonucleotides as modulators of inflammation.

Authors:  Dennis Klinman; Hidekazu Shirota; Debra Tross; Takashi Sato; Sven Klaschik
Journal:  J Leukoc Biol       Date:  2008-04-22       Impact factor: 4.962

5.  CpG oligodeoxynucleotides inhibit tumor growth and reverse the immunosuppression caused by the therapy with 5-fluorouracil in murine hepatoma.

Authors:  Xian-Song Wang; Zhen Sheng; You-Bing Ruan; Yang Guang; Mu-Lan Yang
Journal:  World J Gastroenterol       Date:  2005-02-28       Impact factor: 5.742

6.  Pulmonary Delivery of Nanoparticle-Bound Toll-like Receptor 9 Agonist for the Treatment of Metastatic Lung Cancer.

Authors:  Jillian L Perry; Shaomin Tian; Nisitha Sengottuvel; Emily B Harrison; Balachandra K Gorentla; Chintan H Kapadia; Ning Cheng; J Christopher Luft; Jenny P-Y Ting; Joseph M DeSimone; Chad V Pecot
Journal:  ACS Nano       Date:  2020-06-02       Impact factor: 15.881

7.  CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.

Authors:  Marie Jordan; David J Waxman
Journal:  Cancer Lett       Date:  2015-12-03       Impact factor: 8.679

8.  Route of administration of the TLR9 agonist CpG critically determines the efficacy of cancer immunotherapy in mice.

Authors:  Stefan Nierkens; Martijn H den Brok; Thijs Roelofsen; Jori A L Wagenaars; Carl G Figdor; Theo J Ruers; Gosse J Adema
Journal:  PLoS One       Date:  2009-12-18       Impact factor: 3.240

Review 9.  Toll-like receptor signaling pathways--therapeutic opportunities.

Authors:  Jiankun Zhu; Chandra Mohan
Journal:  Mediators Inflamm       Date:  2010-10-17       Impact factor: 4.711

10.  Peptide vaccine given with a Toll-like receptor agonist is effective for the treatment and prevention of spontaneous breast tumors.

Authors:  Pilar Nava-Parada; Guido Forni; Keith L Knutson; Larry R Pease; Esteban Celis
Journal:  Cancer Res       Date:  2007-02-01       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.